A patient interface including a seal-forming structure with a textile membrane that has at least one hole such that the flow of air at a therapeutic pressure is delivered to at least an entrance to the patients nares and/or an entrance to the patients mouth. The seal-forming structure is constructed and arranged to maintain the therapeutic pressure in a cavity of a plenum chamber throughout the patients respiratory cycle, in use. The textile membrane includes a first portion that is held in a relaxed state and a second portion that is held in a taut state. The taut state of the second portion is configured to allow the seal-forming structure to include a three-dimensional shape that has multiple curvatures.

Disclosed herein in is a medical tube comprising a hydrogenated styrenic block copolymer having a formula A-B-A, (A-B-A).sub.nX or (A-B).sub.nX is disclosed, where n is an integer from 2 to 30, and X is residue of a coupling agent. Prior to hydrogenation, each A block is a monoalkenyl arene homopolymer block having a true peak molecular weight of 5 kg/mol to 15 kg/mol. Each B block is a controlled distribution copolymer block having a true peak molecular weight of 30 kg/mol to 200 kg/mol. The hydrogenated styrenic block copolymer has a midblock poly(monoalkenyl arene) content of 35 wt. % to 50 wt. % based on the total weight of the midblock, and physical properties that makes it useful for producing medical tubes having kink resistance.

This disclosure relates to a medical device including a hard part and a converter. The hard part has fluid paths for conducting a medical fluid through the hard part. The converter is arranged to measure a characteristic of the medical fluid while the medical fluid is present in one of the fluid paths. At least a section of the converter is applied or superimposed to the hard part by at least one additive application method.

An inhaler article (110) comprises a body (112) extending along a longitudinal axis (A) from a mouthpiece end (113) to a distal end (114), a capsule cavity (116) defined within the body, and a distal end element (118) disposed at the distal end and extending to the capsule cavity. The distal end element comprises an element distal end (120), an element inner end (122), a solid core portion (124), and at least two grooves (126). The solid core portion extends from the element distal end to the element inner end. The at least two grooves are helical grooves that rotate about solid core portion along the longitudinal axis from the element distal end to the element inner end. The at least two helical grooves extend along an outer surface (128) of the distal end element.

A method of assembling a drug delivery device, comprising the steps of: inserting a piston rod in a nut portion of a cartridge assembly and rotating the piston rod until the piston rod distal end engages the cartridge piston, mounting a drive member on the piston rod in a rota-tional position being closest to a pre-determined rotational position, and rotating the drive member to the pre-determined rotational position.

The invention relates to an ultrasonic mist inhaler (100), comprising: —a mouthpiece (1) for inhaling the mist, —a liquid reservoir structure (2) comprising a liquid chamber (21) adapted to receive liquid to be atomized, —a sonication chamber (22) in fluid communication with the liquid chamber (21), wherein at least part of the liquid reservoir structure (2) and the mouthpiece (1) form the sonication chamber (22).

An endovascular apparatus including a stabilizing element and a rod that may be detachably coupled to the stabilizing element. The rod may be elongated along a longitudinal axis. The rod may have at least one therapeutic agent thereon. The therapeutic agent may be an enzyme, an antibody, a biomarker, or a bioreceptor for neutralizing components of a bodily fluid of a patient. The rod may be inserted into the patient's body to place the therapeutic agent into fluid communication with the patient's bodily fluid. The rod may be formed from silicone and an outer surface of the rod may be etched prior to coating the rod with the therapeutic agent.

A needle-equipped outer cylinder includes: a needle tube; a joining member comprising: a needle tube accommodation hole that accommodates a proximal end side portion of the needle tube and penetrates the joining member from a distal end of the joining member to a proximal end of the joining member, and a joining outer peripheral portion provided on an outer peripheral portion of the needle tube accommodation hole; and an outer cylinder member comprising: a distal end joint that comprises an inner cavity that receives the joining outer peripheral portion of the joining member from a distal end side, and a projection located at a proximal end portion of the inner cavity and projecting into the inner cavity. The joining member comprises, at a proximal end portion of the joining member, an abutment portion that abuts the projection of the outer cylinder member.

In the preferred embodiment of the present invention, a patch of dissolving microneedles loaded with active ingredients to be applied to skin for treating skin conditions is provided. As seen in FIG. 1, the dissolving microneedle patch (10) comprises a substrate (12) and a plurality of microneedles (14) which extends from the substrate. The dissolving microneedle patch (10) is made of a matrix material and at least one active ingredient such as a corticosteroid, namely triamcinolone (TAC). The matrix material is made of bio-compatible materials such as hyaluronic acid (HA), polyvinylpyrrolidone (PVP), or mixture of them, which dissolve rapidly when they are in contact with the inner skin. The active ingredient is loaded onto individual patches with the desirable dosage ranging from 0.01 mg-1.0 mg.

In the preferred embodiment, a method of making microneedles comprises i) providing a microneedle template (300) having a plurality of microneedles cavities (360) on one surface, ii) preparing a casting solution (320) comprising at least one matrix material and its solvent, iii) subjecting said microneedle template (300) to a vacuum pressure for a length of time to deprive it of air, iv) dispensing the casting solution (320) over the air-deprived microneedle template, v) allowing the casting solution (320) to be drawn into the air-deprived microneedle cavities (360) completely, and vi) allowing the dissolving microneedles to solidify or dry in a controlled environment.